INTRODUCTION {#sec1-1}
============

Age of initiation of substance use during childhood/adolescence has been associated with various long-term health and social complications. Early onset of substance use (EOS) occurs generally in the early to late adolescent period (\<18 years) of age.\[[@ref1]\] Various studies have revealed strong associations between the age of first alcohol/cannabis/cocaine/psychostimulants use and the development of dependence.\[[@ref2][@ref3][@ref4][@ref5][@ref6][@ref7][@ref8]\] Earlier studies had defined early age of onset (more particularly to that of alcohol) to be \<25 years of age.\[[@ref9]\] However, recent literature have highlighted the issue of a more earlier age of onset of substance use, i.e., on or before 17--18 years of age which is mostly the preadolescent and/or adolescent age to be more common and is adversely associated with various psychosocial problems.\[[@ref1][@ref10][@ref11][@ref12][@ref13][@ref14]\] Therefore, newer data suggest to limit the cutoff age to define early and late substance use disorder (SUD) with regard to the age of onset to be at 17 or 18 years of age.\[[@ref1][@ref10][@ref11][@ref12][@ref13][@ref14]\] Apart from having more severe complications and frequent treatment admissions, the individuals with EOS have an early indicator for the development of the psychiatric disorder.\[[@ref1][@ref15][@ref16][@ref17]\] Few studies have demonstrated association between early-onset cannabis use and earlier development of the major depressive disorder, suicidal ideations, and suicidal attempts.\[[@ref18][@ref19][@ref20][@ref21]\]

Epidemiological-based and clinical-based studies had revealed that dual diagnosis (DD) or co-occurring disorders exist in about one-third of patients with SUDs.\[[@ref22][@ref23][@ref24]\] Early age of initiation of substance use and subsequent development of SUD at an early age have been found to be associated with a longer duration of untreated illness of psychiatric disorder and poorer clinical and functional outcomes.\[[@ref25][@ref26][@ref27]\] Poorer treatment-seeking behavior is also linked with EOS group of individuals with DD.\[[@ref28][@ref29][@ref30]\] However, there is currently almost no evidence in the available literature regarding any difference in the clinical characteristics, course, and outcome of patients with DD with respect to the age of onset of substance use (i.e., EOS vs. LOS).

With this background, the current study was intended to compare patients with DD with early-onset of substance use (EOS group) with those with DD with late-onset substance use (LOS group) on various parameters (clinical characteristics, risk behavior, and short-term course and outcome).

MATERIALS AND METHODS {#sec1-2}
=====================

The participants of the present study were outpatients visiting the Drug De-addiction and Treatment Centre (DDTC) at the Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. DDTC, PGIMER caters to 20 inpatients and yearly average of 2500--3000 new patients. Out of all these patients, detail workup is made for yearly average of 700--1000 patients. In the outpatient services of DDTC, PGIMER, all the participants visiting for the first time are evaluated by a qualified psychiatrist, diagnosis is made as per the International Classification of Diseases, 10^th^ revision (ICD-10)\[[@ref31]\] and treatment is initiated. A unique Central Registration Number is assigned to every subject seeking treatment. After an average of 2--3 follow-up visits, the detail workup is done by a trainee psychiatrist in a structured format under the supervision of a qualified psychiatrist and later on is reviewed by the Consultant. During this visit, a DDTC file number is assigned to the subject and if the participant is diagnosed with a comorbid psychiatric disorder, i.e., DD, then an additional DD clinic number is assigned to the same participant. Psychiatric diagnosis was confirmed by two-stage method. The psychiatric diagnosis (both substance use and psychiatric diagnosis) was made clinically by the qualified psychiatrist as per the ICD-10. Later, the diagnosis was confirmed by the consultant. For this study, the DDTC files with DD numbers from 1 to 307 were retrieved and inspected retrospectively. The sociodemographic and clinical details from the detail workup file which included the age of initiation of substance and subsequent development of SUD was recorded. Those with the initiation of substance and onset of clinically diagnosable SUD before the age of 18 years were categorized under the EOS group and others having the initiation of substance use and development of SUD later than 18 years were grouped under the LOS group. The treatment records in these files were analyzed in detail to find out the outcome in terms of no of follow-ups, course of the psychiatric disorder, high-risk behaviors, and consequences in various domains (health, social, marital, family, legal, and occupation). The study protocol was approved by the Institutional Ethical Review Board of the Institute.

Statistical analysis {#sec2-1}
--------------------

The analysis was performed using SPSS software version 16 (Statistical Package for the Social Sciences, Chicago, IL, USA). Frequencies and percentages were computed for discontinuous sociodemographic and clinical variables. Mean and standard deviation (SD) for the continuous variables were calculated. Both the groups were compared using *t*-test, Chi-square test, Fisher\'s exact test, and Yate\'s correction wherever applicable. For multiple comparisons, Bonferonni *post hoc* test correction was carried out. The statistical significance was kept at *P* \< 0.05.

RESULTS {#sec1-3}
=======

Of the 307 patients with DD, 100 patients had the initiation of substance use and development of SUD before \<18 years of age and were categorized into the EOS group and rest 207 patients fell into the LOS group. Both the groups were compared across different variables.

Sociodemographic profile {#sec2-2}
------------------------

As evident from [Table 1](#T1){ref-type="table"}, the difference in age at first presentation to our services in both the groups was statistically significant. There were no females in the EOS group and only four females in the LOS group, but it was not statistically significant. More married and employed individuals were present in the LOS group and the difference was significant too. However, there was no difference in the level of education, locality, religion, and type of family in both the groups.

###### 

Comparison of sociodemographic parameters between early onset (EOS; *n*=100) and late onset (LOS; *n*=207) substance use group

  Parameters                Mean (SD)/*n* (%)             *t*-test/*χ*^2^ (*P*)          
  ------------------------- ----------------------------- ------------------------------ -----------------------------------------------
  Age at presentation       29.56 (9.52) (range: 14-67)   39.35 (11.21) (range: 19-84)   *t*=−7.516 (\<0.001)\*\*\* (CI: −12.35-−7.22)
  Sex                                                                                    
   Male                     100 (100)                     203 (98.1)                     *χ*^2^=1.95 (0.161)
   Female                   0                             4 (1.9)                        
  Education                                                                              
   Illiterate               7 (7)                         11 (5.3)                       *χ*^2^=0.381 (0.943)
   Under matric             23 (23)                       48 (23.18)                     
   Matriculate              25 (25)                       51 (24.6)                      
   Above matric             45 (45)                       97 (46.8)                      
  Marital status                                                                         
   Single                   50 (50)                       43 (20.7)                      *χ*^2^=27.33 (\<0.001)\*\*\*
   Married                  48 (48)                       156 (75.4)                     
   Divorced                 2 (2)                         8 (3.86)                       
  Occupation                                                                             
   Unemployed               52 (52)                       53 (25.6)                      *χ*^2^=20.87 (\<0.001)\*\*\*
   Employed on paid wages   48 (48)                       154 (74.3)                     
  Religion                                                                               
   Hindu                    63 (63)                       130 (62.8)                     *χ*^2^=0.001 (0.973)
   Non-Hindu                37 (37)                       77 (37.1)                      
  Family type                                                                            
   Nuclear                  58 (58)                       102 (49.3)                     *χ*^2^=2.05 (0.151)
   Nonnuclear               42 (42)                       105 (50.7)                     
  Locality                                                                               
   Urban                    55 (55)                       118 (57)                       *χ*^2^=0.11 (0.739)
   Rural                    45 (45)                       89 (42.9)                      

\**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001. SUD -- Substance use disorders; SD -- Standard deviation; CI -- Confidence interval; EOS -- Early onset substance use disorder; LOS -- Late onset substance use disorder

Clinical profile of the two groups {#sec2-3}
----------------------------------

As depicted in [Table 2](#T2){ref-type="table"}, the mean age of onset of primary substance use in the EOS and LOS group was 15.65 (SD -- 2.33) years of age and 25.51 (SD -- 6.74) years, respectively. However, no difference was noted in the mean duration (in months) of the dependence of primary substance in both groups. The age of onset of psychiatric disorder in both the groups was found to be statistically significant (EOS -- 23.25 \[SD -- 8.55\] vs. LOS -- 32.44 \[SD -- 10.99\]; *P* \< 0.001). In both groups, alcohol was the primary substance abused (EOS -- 43% vs. LOS -- 59.9%). However, cannabis as the primary substance was more prevalent in the EOS (30%) than the LOS group (12.6%). Overall, the difference in the prevalence of primary substance use in both groups was statistically significant for alcohol (*P* = 0.005), tobacco (*P* = 0.001), and cannabis (*P* \< 0.001). While more number of participants in the EOS group had a history of admission to hospital (40%) as compared to the LOS group (28.5%), more number of participants in the LOS group had a poor outcome after admission (EOS -- 24% vs. LOS -- 54.5%; *P* = 0.005). With regard to the diagnosis of psychiatric disorder in both groups, psychotic disorders were more prevalent in the EOS group (41%) followed by affective/mood disorders (30%) while the reverse was true in the LOS group (56.5%, 27.5%) \[[Figure 1](#F1){ref-type="fig"}\]. However, the statistical significant difference after applying correction for multiple comparisons was only for psychotic disorders (*P* = 0.018) and affective disorders (*P* \< 0.001). Anxiety disorders were the third-most common psychiatric diagnosis in both groups. There was no difference in the presence/absence of externalizing symptoms, history of treatment by faith healers, and family history of SUD in both the groups.

###### 

Comparison of clinical profile EOS versus LOS

  Parameters                                              Mean (SD)/*n* (%)                *t*-test/*χ*^2^ (*P*)           
  ------------------------------------------------------- -------------------------------- ------------------------------- ------------------------------------------------------------
  Age of initiation of primary substance use              15.65 (2.33)                     25.51 (6.74)                    *t*=−14.206 (\<0.001)\*\*\* (CI: −11.22-−8.49)
  Duration in months of dependence of primary substance   128.38 (96.48) (range: 10-456)   127.35 (97.70) (range: 2-480)   *t*=0.086 (0.931) (CI: −22.31-24.36)
  Number of substance dependence                                                                                           
   1                                                      15 (15)                          48 (23.2)                       *χ*^2^=4.355 (0.226)
   2                                                      46 (46)                          97 (46.9)                       
   3                                                      30 (30)                          51 (24.6)                       
   \>3                                                    9 (9)                            11 (5.3)                        
  Most common primary substance                                                                                            
   Alcohol                                                43 (43)                          124 (59.9)                      *χ*^2^=7.766 (0.005)\*
   Tobacco                                                11 (11)                          4 (1.9)                         *χ*^2^=11.930 (0.001)\*\*\*
   Cannabis                                               30 (30)                          26 (12.6)                       *χ*^2^=13.751 (\<0.001)\*\*\*
   Opioids                                                15 (15)                          47 (22.7)                       *χ*^2^=2.484 (0.115)
   Sedatives/hypnotics                                    1 (1)                            5 (2.4)                         *χ*^2^=0.705 (0.401)
   Inhalants                                              0                                1 (0.5)                         *F*=0.001 Adjusted *post hoc* *χ*^2^=29.28 (\<0.001)\*\*\*
  Age of onset of psychiatric disorder                    23.25 (8.55) (range: 2-55)       32.44 (10.99) (range: 7-83)     *t*=−7.354 (\<0.001)\*\*\* (CI: −11.65-−6.73)
  Classification of psychiatric disorder                                                                                   
   F00-F09                                                1 (1)                            1 (0.5)                         *χ*^2^=0.546F
   F20-F29                                                41 (41)                          57 (27.5)                       *χ*^2^=5.624 (0.018)\*
   F30-F39                                                30 (30)                          117 (56.5)                      *χ*^2^=19.005 (\<0.001)\*\*\*
   F40-F48                                                20 (20)                          27 (13.0)                       *χ*^2^=2.517 (0.113)
   F50-F59                                                0                                2 (1.0)                         *F*=1.000
   F60-F69                                                3 (3)                            2 (1.0)                         *F*=0.334
   F70-F79                                                2 (2)                            0                               *F*=0.105
   F90-F98                                                3 (3)                            1 (0.5)                         *F*=0.103 Adjusted *post hoc* *χ*^2^=26.23 (\<0.001)\*\*\*
  Past history of admission                                                                                                
   Yes                                                    40 (40)                          59 (28.5)                       *χ*^2^=4.080 (0.043)\*
   No                                                     60 (60)                          148 (71.49)                     
  Outcome of admission                                                                                                     
   Improved                                               56 (56)                          94 (45.4)                       *χ*^2^=13.984 (\<0.001)\*\*\*
   Not improved                                           24 (24)                          113 (54.5)                      
  History of externalizing symptoms                                                                                        
   Yes                                                    31 (31)                          35 (16.9)                       *χ*^2^=7.934 (0.005)\*\*
   No                                                     69 (69)                          172 (83.1)                      
  History of treatment by faith-healers                                                                                    
   Yes                                                    13 (13)                          27 (13)                         *χ*^2^=0.00001 (0.991)
   No                                                     87 (87)                          180 (87)                        
  Family history of substance dependence                                                                                   
   Yes                                                    46 (46)                          87 (42)                         *χ*^2^=0.433 (0.511)
   No                                                     54 (54)                          120 (58)                        

\**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001. SD -- Standard deviation; CI -- Confidence interval; EOS -- Early onset substance use disorder; LOS -- Late onset substance use disorder

![Psychiatric disorders in the early onset substance use disorder (EOS) and late onset substance use disorder (LOS) dual diagnosis patients groups](IJPsy-61-359-g001){#F1}

Comparison of clinical parameters in both the groups {#sec2-4}
----------------------------------------------------

EOS group had both onset of tobacco use and development of dependence at an earlier age as compared to LOS group and the difference was statistically significant in both cases \[[Table 3](#T3){ref-type="table"}\]. Both the groups had the almost the same number of participants with intravenous drug use. There was more prevalence of unprotected sexual intercourse, multiple sexual partners, and history of sexual intercourse with commercial sex workers (CSW), history of premarital sexual contact in the EOS group as compared to the LOS group, the difference in all these parameters being significant statistically. With regard to nature of the psychiatric disorder, both the groups did not differ in relation to number of relapse of psychiatric illness due to poor drug compliance, number of relapses, family history of psychiatric disorder, and history of suicide attempt. However, there was more continuous type of psychiatric illness in the EOS group than the episodic type of illness in the LOS group. Clinical insight of psychiatric illness was absent in more subjects in the EOS group, the difference being significant statistically.

###### 

Comparison of clinical parameters in both the groups

  Clinical parameters                                           Mean (SD)/*n* (%)     *t*-test/*χ*^2^ (P)    
  ------------------------------------------------------------- --------------------- ---------------------- ------------------------------------------
  Age of onset of tobacco use                                   *n*=82 18.06 (3.80)   *n*=149 21.75 (5.57)   *t*=−5.345 (0.003)\*\* (CI: −5.05-−2.33)
  Age of tobacco dependence                                     *n*=82 19.10 (3.84)   *n*=149 22.97 (5.22)   *t*=−5.898 (0.024)\* (CI: −5.17-−2.58)
  IDU parameters                                                *n*=100               *n*=207                
   ID dependence                                                3 (3)                 7 (3.4)                *χ*^2^=0.001 (1.00)
   History of IDU by IV route                                   3 (3)                 6 (2.9)                *χ*^2^=0.001 (1.00)
   Sharing of needles                                           3 (3)                 2 (1)                   F=1.74 (0.334)
   Sharing of mixer/vials/cottons                               2 (2)                 4 (1.9)                F=0.002 (1.00)
   Sharing of syringes                                          2 (2)                 2 (1)                  F=0.56 (0.599)
   Reuse of needles/syringes                                    2 (2)                 3 (1.4)                F=0.106 (1.00)
  History of unprotected sexual intercourse                                                                  
   Present                                                      14 (14)               9 (4.3)                *χ*^2^=9.064 (0.003)\*\*
  History of multiple sexual partners                                                                        
   Present                                                      14 (14)               11 (5.3)               *χ*^2^=6.801 (0.009)\*\*
  History of sexual intercourse with CSW                                                                     
   Present                                                      16 (16)               17 (8.2)               *χ*^2^=4.262 (0.039)\*
  History of premarital sexual intercourse                                                                   
   Present                                                      12 (12)               9 (4.3)                *χ*^2^=6.196 (0.013)\*
  History of surreptitious use of medications                                                                
   Present                                                      33 (33)               49 (23.7)              *χ*^2^=2.997 (0.083)
  Relapse of psychiatric illness due to poor drug compliance                                                 
   Present                                                      55 (55)               104 (50.2)             *χ*^2^=0.611 (0.434)
  Number of relapses of psychiatric illness                     1.11 (1.12)           1.02 (1.14)            *χ*^2^=0.652 (0.715)
  Family history of psychiatric illness                                                                      
   Present                                                      34 (34)               76 (36.7)              *χ*^2^=0.216 (0.642)
  History of involuntary admission due to psychiatric illness                                                
   Present                                                      15 (15)               34 (16.4)              *χ*^2^=0.102 (0.749)
  Course of psychiatric illness                                                                              
   Continuous                                                   75 (75)               126 (60.9)             *χ*^2^=5.955 (0.015)\*
   Episodic                                                     25 (25)               81 (39.1)              
  History of suicide attempt                                                                                 
   Present                                                      17 (17)               33 (15.9)              *χ*^2^=0.055 (0.814)
  Insight of psychiatric illness                                                                             
   Absent                                                       33 (33)               51 (24.6)              *χ*^2^=6.09 (0.048)\*
   Partial                                                      50 (50)               95 (45.9)              
   Present                                                      17 (17)               61 (29.5)              

\**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001. F -- Fischer's exact. SD -- Standard deviation; CI -- Confidence interval; EOS -- Early onset substance use disorder; LOS -- Late onset substance use disorder; IDU -- Intravenous drug use; IV -- Intravenous; CSW -- Commercial sex worker; ID -- Intravenous drugs

Comparison of substance use disorder-related consequences in both groups {#sec2-5}
------------------------------------------------------------------------

Although there were several SUD-related complications at the time of initial presentation in both the groups, there was no difference between the two groups statistically \[as evident from [Table 4](#T4){ref-type="table"}\].

###### 

Comparison of substance use disorders related complications

  Complications        Frequency (%)   *χ*^2^ (*P*)   
  -------------------- --------------- -------------- ----------------------
  Health related                                      
   Nil                 20 (20)         50 (24.2)      *χ*^2^=1.471 (0.689)
   Mild                37 (37)         81 (39.1)      
   Moderate            41 (41)         71 (34.3)      
   Severe              2 (2)           5 (2.4)        
  Occupation related                                  
   Nil                 15 (15)         46 (22.2)      *χ*^2^=2.60 (0.457)
   Mild                48 (48)         90 (43.5)      
   Moderate            31 (31)         56 (27.1)      
   Severe              6 (6)           15 (7.2)       
  Finance related                                     
   Nil                 25 (25)         59 (28.5)      *χ*^2^=2.78 (0.427)
   Mild                42 (42)         91 (44.0)      
   Moderate            32 (32)         51 (24.6)      
   Severe              1 (1)           6 (2.9)        
  Legal related                                       
   Nil                 71 (71)         146 (70.5)     *χ*^2^=4.010 (0.260)
   Mild                27 (27)         55 (26.6)      
   Moderate            2 (2)           1 (0.5)        
   Severe              0               5 (2.4)        
  Family related                                      
   Nil                 26 (26)         71 (34.3)      *χ*^2^=2.158 (0.540)
   Mild                52 (52)         96 (46.4)      
   Moderate            21 (21)         38 (18.4)      
   Severe              1 (1)           2 (1.0)        
  Marital related                                     
   Nil                 50 (50)         77 (37.2)      *χ*^2^=3.441 (0.064)
   Mild                38 (38)         100 (48.3)     
   Moderate            11 (11)         28 (13.5)      
   Severe              1 (1)           2 (1.0)        
  Social related                                      
   Nil                 26 (26)         68 (32.9)      *χ*^2^=2.419 (0.548)
   Mild                59 (59)         105 (50.7)     
   Moderate            15 (15)         33 (15.9)      
   Severe              0               1 (0.5)        

EOS -- Early onset substance use disorder; LOS -- Late onset substance use disorder

Comparison of short-term course and outcome {#sec2-6}
-------------------------------------------

At 1-month follow-up, more subjects in the EOS group worsened than the LOS group in relation to SUD (21% vs. 1%; *P* \< 0.001). At 3-month follow-up, no difference between the groups with regard to either psychiatric disorder or SUD was noted. In addition, when evaluated at 6 months it was seen that the subjects that followed up in the clinic (EOS: 39%; LOS: 34%; *P* \> 0.05), outcome was noted as improved in the EOS group compared to LOS group regarding both psychiatric disorder (87% vs. 62%; *P* = 0.007) and SUD (82% vs. 62%; *P* = 0.012), despite a further drop in the follow-ups in both the groups (which was comparable in both the groups (Follow-up: EOS -- 39% vs. LOS -- 34.29%) \[[Table 5](#T5){ref-type="table"}\].

###### 

Comparison of follow up status in both groups

  ------------------------------------------------------------------------------------------------------------------------------------
  Follow up status                      Mean (SD)/*n* (%)           *t*-test/*χ*^2^ (*P*)      
  ------------------------------------- --------------------------- -------------------------- ---------------------------------------
  Number of follow ups                  1.50 (1.106) (range: 0-4)   1.37 (1.21) (range: 0-5)   *t*=0.924 (0.356) (CI: −0.15-0.416)

  Adherence                                                                                    

   Poor                                 30 (30)                     77 (37.19)                 *χ*^2^=1.54 (0.462)

   \>50                                 24 (24)                     45 (21.7)                  

   \>75                                 46 (46)                     85 (41.1)                  

  Compliance                                                                                   

   Yes                                  67 (67)                     121 (58.5)                 *χ*^2^=2.075 (0.149)

   No                                   33 (33)                     86 (41.5)                  

  Motivation                                                                                   

   Precontemplation                     43 (43)                     99 (47.8)                  *χ*^2^=0.836 (0.840)

   Contemplation                        37 (37)                     71 (34.3)                  

   Preparation                          12 (12)                     20 (9.7)                   

   Action                               8 (8)                       17 (8.2)                   

   Maintenance                          0                           0                          

  Insight                                                                                      

   Absent                               28 (28)                     75 (36.23)                 *χ*^2^=4.707 (0.095)

   Partial                              46 (46)                     69 (33.3)                  

   Full                                 26 (26)                     63 (30.4)                  

  Outcome of psychiatric disorder                                                              

   Worsened                             0                           3 (1.4)                    *χ*^2^=2.096 (0.350)

   Unchanged                            35 (35)                     81 (39.13)                 

   Improved                             65 (65)                     123 (59.4)                 

  Outcome of substance dependence                                                              

   Worsened                             21 (21)                     2 (1.0)                    *χ*^2^=48.877 (\<0.001)

   Unchanged                            17 (17)                     87 (42.02)                 

   Improved                             62 (62)                     118 (57.0)                 

                                                                                               

  **At 3 months**                                                                              

                                                                                               

  Number of follow ups                  *n*=85\                     *n*=175\                   *t*=0.828 (0.409) (CI: −0.225-0.552)
                                        1.52 (1.436) (range: 0-6)   1.35 (1.52) (range: 0-6)   

  Adherence                                                                                    

   Poor                                 52 (61.11)                  15 (7.24)                  *χ*^2^=92.26 (\<0.001)\*\*\*

   \>50                                 10 (11.76)                  106 (60.57)                

   \>75                                 23 (27.05)                  54 (26.08)                 

   Compliance                                                                                  

   Yes                                  45 (45)                     73 (35.3)                  *χ*^2^=2.909 (0.088)

   No                                   40 (47.05)                  102 (58.28)                

  Motivation                                                                                   

   Precontemplation                     57 (67.05)                  45 (25.71)                 *χ*^2^=54.44 (\<0.001)\*\*\*

   Contemplation                        22 (25.88)                  80 (45.71)                 

   Preparation                          3 (3.52)                    50 (28.57)                 

   Action                               3 (3.52)                    0                          

   Maintenance                          0                           0                          

  Insight                                                                                      

   Absent                               18 (21.17)                  6 (2.9)                    *χ*^2^=23.58 (\<0.001)\*\*\*

   Partial                              55 (64.70)                  123 (70.28)                

   Full                                 12 (14.11)                  46 (22.2)                  

  Outcome of psychiatric disorder                                                              

   Worsened                             2 (2.35)                    3 (1.4)                    *χ*^2^=2.409 (0.299)

   Unchanged                            36 (42.35)                  92 (52.5)                  

   Improved                             47 (55.29)                  80 (38.6)                  

  Outcome of substance dependence (%)                                                          

   Worsened                             2 (2.35)                    7 (4)                      *χ*^2^=0.662 (0.718)

   Unchanged                            42 (49.41)                  90 (51.42)                 

   Improved                             41 (48.23)                  78 (37.7)                  

                                                                                               

  **Follow ups at 6 months**                                                                   

                                                                                               

  Number of follow ups                  *n*=39\                     *n*=71\                    *t*=−0.715 (0.412) (CI: −0.805-0.378)
                                        2.31 (1.52) (range: 1-9)    2.52 (1.48) (range: 1-9)   

  Adherence                                                                                    

   Poor                                 6 (15.4)                    14 (19.7)                  *χ*^2^=2.284 (0.319)

   \>50                                 8 (20.5)                    22 (31)                    

   \>75                                 25 (64.1)                   35 (49.3)                  

  Compliance                                                                                   

   Yes                                  32 (82.1)                   45 (63.4)                  *χ*^2^=4.179 (0.041)\*

   No                                   7 (17.9)                    26 (36.6)                  

  Motivation                                                                                   

   Precontemplation                     7 (17.9)                    17 (23.9)                  *χ*^2^=4.87 (0.301)

   Contemplation                        15 (38.5)                   24 (33.8)                  

   Preparation                          3 (7.7)                     11 (15.5)                  

   Action                               14 (35.9)                   17 (23.9)                  

   Maintenance                          0                           2 (2.8)                    

  Insight                                                                                      

   Absent                               3 (7.7)                     4 (5.6)                    *χ*^2^=0.662 (0.718)

   Partial                              12 (30.8)                   27 (38.0)                  

   Full                                 24 (61.5)                   40 (56.3)                  

  Outcome of psychiatric disorder                                                              

   Worsened                             0                           10 (14.1)                  *χ*^2^=8.766 (0.007)

   Unchanged                            5 (12.8)                    17 (23.9)                  

   Improved                             34 (87.17)                  44 (62)                    

   Outcome of substance dependence                                                             

   Worsened                             0                           9 (12.7)                   *χ*^2^=8.027 (0.012)

   Unchanged                            7 (17.9)                    18 (25.3)                  

   Improved                             32 (82.1)                   44 (62.0)                  
  ------------------------------------------------------------------------------------------------------------------------------------

\**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001. SD -- Standard deviation; CI -- Confidence interval; EOS -- Early onset substance use disorder; LOS -- Late onset substance use disorder

DISCUSSION {#sec1-4}
==========

The present study aimed to find out whether there was any relationship between the age of initiation of substance use in patients with DD in the overall course and outcome of DD. To the best of our knowledge, this is the first study in this regard from a tertiary drug de-addiction center in India. Although it was a retrospective study, every possible effort was made to document and analyze all variables related to the diagnosis and management of every subject included in the study.

In the present study, we assessed the treatment details and follow-up data of 307 patients with DD and based on age cutoff of 18 years, the cases were recruited into EOS and LOS group. As evident from the results, participants in the EOS group presented to the healthcare services earlier. It can be because earlier the substance use and development of dependence, earlier is the dysfunction noted in academic, social and work domains by the caregivers and early is the treatment sought by the family. This is in accordance with the report by Substance Abuse and Mental Health Services Administration report\[[@ref10]\] which also suggested that 74% of treatment admissions from age 18 to 30 years had the initiation of substance by the age of 17 years or less. Thereby, we can suggest that it is not an uncommon scenario in the adolescent age group to initiate substance earlier.

The mean age of onset of primary substance use in our EOS group was 15.65 (SD -- 2.33) years, which is in accordance with the previous studies regarding the age of onset of substance abuse.\[[@ref3][@ref4][@ref32][@ref33][@ref34][@ref35][@ref36]\] Although in both the groups, more number of participants were dependent on two substances, yet about 40% of participants in the EOS group were dependent on \>3 substances which about 10% was less in the LOS group. Existing literature also supports this view that earlier the age of onset of substance, more is the prevalence of polysubstance dependence.\[[@ref1][@ref37][@ref38]\] Alcohol was more common in both groups, but cannabis was the second-most prevalent substance in the EOS group. Similar findings have been reported by various studies which have reported cannabis to be more commonly abused by adolescents worldwide.\[[@ref39][@ref40][@ref41][@ref42]\] Higher prevalence of cannabis use has also been regarded as a predictor of subsequent initiation with other illicit and licit drugs or commonly known as the "gateway hypothesis" in the adolescent population.\[[@ref43][@ref44][@ref45][@ref46]\] With regard to tobacco use, the EOS group had very early onset of initiation and subsequent dependence and the same had been replicated across several studies. In addition, studies have also reported a strong relationship between early-onset regular smoking to later alcohol use and other risky behaviors in adolescence.\[[@ref6][@ref47][@ref48][@ref49]\]

When we introspect about the nature of the psychiatric illness in the two groups, a higher prevalence of psychotic disorders in the EOS group and a higher prevalence of affective disorders in the LOS group were noted. Studies which have evaluated first episode psychosis (mostly in adolescents) have found a high prevalence of comorbid SUD and more particularly cannabis in this age group.\[[@ref50][@ref51][@ref52][@ref53][@ref54][@ref55]\] Similarly, studies which have tried to link between substance abuse and affective disorders/Bipolar disorder have found the association of alcohol use/dependence after 18 years of age.\[[@ref56][@ref57][@ref58][@ref59]\] Few Indian studies on patients with DD have also reported a higher prevalence of affective disorders and anxiety disorders.\[[@ref60][@ref61][@ref62][@ref63]\] However, we were unable to find any previous Indian/Western studies which had tried to compare EOS and LOS patients with DD.

As compared to the LOS group, the EOS group had more high-risk sexual behavior in the form of unprotected sexual encounter, multiple sexual partners, and sexual encounter with CSW. This is also been replicated across several studies that earlier age of onset of SUD has been associated with high-risk sexual behaviors,\[[@ref64]\] infrequent condom use and pregnancy,\[[@ref65][@ref66]\] sexually-transmitted diseases,\[[@ref67]\] violence,\[[@ref68]\] depression, and suicide.\[[@ref69][@ref70][@ref71]\] With regard to high-risk sexual behavior in those who had early initiation of substance use and subsequent early development of SUD, the role of difficult temperament could not be excluded as it has been well established from number of studies that temperamental characteristics increases one\'s to various risk-taking behaviors early in the childhood.\[[@ref72][@ref73][@ref74]\] Although in this study, we were unable to find any association between temperament and sexual risk behaviors, there is evidence of the high prevalence of sexual risky behaviors in the EOS group suggesting temperamental predisposition.

As far as the SUD-related consequences are concerned, no significant differences were found between the two groups on the various psycho-social-legal domains. It could be because most of the participants with DD had a similar profile of SUD-related complications at the time of presentation. This is in contrast to some studies which have found earlier age of onset of SUD to be associated with more severe psychosocial problems.\[[@ref11][@ref75]\]

Another aspect of the present study was to look for any difference in the short-term outcome with regard to follow-up patterns in the two groups. From the study findings, we are able to conclude that (1) At 1 month follow-up, there was not much difference between the two groups in different parameters of adherence, compliance to treatment, insight about psychiatric illness, and outcome of psychiatric illness. Only difference was noted in the worsening in the short-term outcome of SUD in about one-fifth of patients in the EOS-DD group which can be related to the difficulties usually encountered while treating adolescents with SUD\[[@ref76][@ref77][@ref78][@ref79]\] and nature of psychiatric illness (mostly psychosis) during initial phases of treatment (2) At 3-month follow-up, despite comparable dropout rates in both the groups, there was a significant difference noted in the adherence rates in the EOS group which was poorer (in those retained in the study after 3 months) than the LOS group. In addition, there was more number of subjects in the EOS-DD group who had the poor motivation to quit substances even at the end of 3 months suggesting that there are several difficulties in ensuring motivation to quit substances in early-onset SUD.\[[@ref11][@ref76]\] However, by 3 months, there was not much difference in the short-term outcome of psychiatric illness and substance dependence in both the groups which further suggested that more the contact with treatment services, better is the outcome whether it is EOS or LOS. Retention in the treatment network is the cornerstone of improvement in individuals with DD.\[[@ref80][@ref81][@ref82][@ref83]\] (3) At the end of 6 months, despite similar dropout rates in both groups, there was a significant difference noted in the outcome of psychiatric illness and SUD, i.e., EOS group had better outcome in both psychiatric illness and SUD as compared to the LOS group. This can be because that there was more number of subjects with psychotic disorders or cannabis-induced psychotic disorders in the EOS group and keeping them in the treatment net could have possibly led to better outcome in the EOS group with regard to more number of participants with affective disorders in the LOS group which possibly be having an episodic course with periodic relapses leading to more number of unchanged outcome.

We are well aware of our limitations. It was a retrospective study, and there is every possibility that many facts regarding the illness may not have been documented or would have been missed to be documented in the DD case files. The sample was limited to clinic-based treatment-seeking subjects and hence could not be generalized to the community. The study was based on clinical assessment only, without any instrumental or laboratory validation. Moreover, another important limitation of the present study was the short-term outcome was based on those subjects (in both groups) retained in follow-up. Further, we did not use any instrument to measure adherence, compliance, motivation, and insight and these assessments were limited to the assessment clinically by the treating psychiatrists during the follow-ups. All these parameters were rated as per the notes in the available treatment records, and there could be subjective/therapist variation in interpreting the same. Further, it is also a known fact that different SUDs have different clinical courses and have different psychosocial trajectories. However, to demonstrate the impact of age of onset of substance use and subsequent development of SUD of any substance category, we have clubbed all the SUDs into one category. Although it would have been ideal to analyze all the sub-groups, the sample size was too small to go for multiple subgroup analysis. Future studies with a larger sample size should overcome these limitations.

CONCLUSIONS {#sec1-5}
===========

Despite the above limitations, the present study provided for the first time that there are significant differences in the clinical characteristics, psychiatric diagnosis, and risk behaviors in patients with DD based on the age of onset of SUD suggesting that the short-term course and outcome of patients with DD could be different if taken into account the age of onset of SUD. Of those retained in the follow-up, patients with EOS may actually fare better than the LOS group. This is a new finding that may be due to the type of substances used and type of psychiatric disorders in the EOS group. This study lays the foundation of further prospective studies, which if replicated with appropriate instruments, might have important management implications in DD patients.
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